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1. Introduction 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). 
The prevalence of MS is approximately 2 million people worldwide, with an incidence of 
about 1:1000 in Europe and Northern America, and women are affected more often compared 
to men, at a ratio of approximately 2:1. It is the most common cause of neurological 
disability among young adults with an onset generally between 20 and 40 years of age 
[Pugliatti et al., 2002]. The major neuropathological hallmarks of MS are demyelinating 
lesions associated with perivascular infiltrates, consisting of macrophages/microglia and 
lymphocytes. The lesions are characterized by destruction of myelin sheaths, oligodendrocyte 
death, axonal damage and glial scar formation, called astrogliosis. Demyelination is a central 
event in MS pathology. Although some remyelination occurs, it ultimately fails [Franklin, 
2002]. The cause of the remyelination failure is not clear, although several processes have 
been suggested to play a role [Franklin and Ffrench-Constant, 2008; Wolswijk, 2002; John et 
al., 2002]. Not only processes behind remyelination failure remain elusive, also the cellular 
mechanisms behind the demyelination and axonal damage are largely unknown. Modelling 
MS both in animals and in vitro could help with understanding this.  
This chapter will focus on MS pathology and the models that exist for investigating this 
disease, especially zooming in on in vitro models. 
2. Multiple sclerosis 
2.1 Clinical symptoms and diagnosis  
MS is characterized by multiple sclerotic lesions affecting areas such as the cerebellum, 
cerebrum (periventricular white matter), optic nerve, brainstem and spinal cord [Compston 
and Coles, 2008]. The clinical symptoms of MS are very heterogeneous depending on the 
location, size and number of lesions. Symptoms include motor function disturbances, such 
as muscle weakness, tremor and paralysis, and progressive sensory malfunction, for 
instance impaired vision. The main criterion for diagnosis of MS is the occurrence of two (or 
more) independent episodes of clinical symptoms consistent with focal demyelination 
separated in space (part of the CNS) and time (more than one occasion) [Polman et al., 2011; 
McDonald et al., 2001]. Magnetic resonance imaging (MRI) techniques have become very 
important for verification of diagnosis [Barkhof et al., 1997; Nielsen et al., 2005; Polman et  
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al., 2005], for detection of the number and size of the lesions and to differentiate between 
ongoing inflammation and blood-brain-barrier leakage [Bruck et al., 1997; Miller et al., 1998; 
Nesbit et al., 1991; Katz et al., 1993]. The presence of oligoclonal bands in cerebrospinal  
fluid (CSF) of MS patients and elevated immunoglobulin G (IgG) levels are supportive of 
MS diagnosis [Polman et al., 2011]. Furthermore, they corroborate the inflammatory 
demyelinating nature of the underlying condition, are used to evaluate alternative 
diagnoses and to predict clinical definite MS [Correale and de los Milagros Bassani Molinas, 
2002]. In approximately 90% of MS patients oligoclonal immunoglobulin bands are detected 
[Bourahoui et al., 2004]. These oligoclonal bands are also detected in other neurological 
diseases, although not as consistently and persistently as in MS. In patients with clinically 
isolated syndrome the presence of oligoclonal bands is predictive for the progression to 
clinically definite MS [Paolino et al., 1996]. In MS patients the absence of oligoclonal bands is 
associated with a benign disease course, while high levels of oligoclonal bands are 
correlated with a severe disease, suggesting that oligoclonal bands may be clinically relevant 
[Correale and de los Milagros Bassani Molinas, 2002]. The identification of biomarkers for 
diagnosis and prognosis of MS is the subject of intense ongoing research [Teunissen et al., 
2011; Ziemann et al., 2011; Junker et al., 2011; Teunissen et al., 2009]. One example is 
neurofilament light, which was found to be increased in clinically isolated syndrome 
patients, especially in those that converted to MS, and was observed to correlate with 
relapses and the number of gadolinium enhancing lesions [Teunissen et al., 2009].   
Four major subtypes of MS with different progression and relapse characteristics have been 
recognized: the relapsing-remitting (RR-MS), the secondary-progressive (SP-MS), primary 
progressive (PP-MS) and progressive-relapsing (PR-MS) subtype [Lublin and Reingold, 
1996]. Approximately 70% of the cases start with the RR subtype, which is characterized by 
clinical attacks that are followed by a clinically silent period with almost complete recovery. 
After a period of 15 to 20 years most cases of the RR-MS subtype develop progressive 
neurological deterioration without apparent remission, the SP-MS subtype. About 15-20% of 
MS patients show a progressive disease course without relapses and remissions from the 
beginning, the PP-MS subtype. Finally, less than 5% suffer from PR-MS, characterized by 
progressive neurological impairment with occasional relapses.  
2.2 Pathology 
The major neuropathological hallmarks of MS are multiple focal inflammatory 
demyelinating lesions spread throughout the CNS. These lesions are associated with 
perivascular infiltrates containing macrophages and lymphocytes. Other features of MS 
plaques are axonal damage and loss, oligodendrocyte death and astrogliosis [Charcot, 1868], 
which is hypertrophy and an abnormal increase in the number of astrocytes. Lesions are 
classified based on the degree of myelin loss, the presence of inflammatory cells and HLA-
DR expression on leukocytes and microglial cells. Four different stages in MS lesions have 
been identified: (p)reactive, active, chronic active and chronic inactive lesions [van der Valk 
and De Groot, 2000; de Groot et al., 2001].  
In (p)reactive lesions no demyelination is apparent. Clusters of activated microglia can be 
observed with increased expression of HLA-DR expression and occasionally perivascular 
leukocyte infiltrations can be seen.  
Active lesions are characterized by areas of demyelination containing macrophages, 
activated microglia and activated hypertrophic astrocytes. Activated astrocytes fill up the 
lesion area and form a gliotic scar. T-cells and some B-cells can be found, mostly in the 
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perivascular space. The macrophages and microglia in the lesions contain myelin 
degradation products, such as myelin proteins and lipids, giving them a foamy appearance. 
The presence of myelin proteins in these macrophages reflect ongoing demyelination, since 
these myelin proteins are degraded in a known time frame [Bruck et al., 1995; van der Goes 
A. et al., 2005]. Oligodendrocyte death occurs in these lesions, often via apoptotic 
mechanisms [Wolswijk, 2000; Rodriguez and Lucchinetti, 1999]. This apoptosis of 
oligodendrocytes may be a disease initiating event, since it precedes leukocyte infiltration 
[Barnett and Prineas, 2004; Henderson et al., 2009].  
Chronic active lesions are defined by a hypocellular demyelinated centre surrounded by a 
hypercellular rim with high numbers of foamy macrophages and reactive astrocytes. In 
these lesions oligodendrocyte numbers are reduced and lymphocytes are present in 
perivascular spaces. 
In chronic inactive lesions almost no cellular infiltrates are present. They are hypocellular, 
demyelinated and contain widened extracellular spaces and gliotic scar tissue. In the CNS 
parenchyma and perivascular spaces relatively small numbers of macrophages and 
lymphocytes still remain. No myelin proteins can be detected in the macrophages. 
Next to demyelination, remyelination also occurs [Franklin, 2002]. Remyelination can be 
restricted to the lesion edge, but can also extend throughout the lesions which are then 
called shadow-plaques [Bruck et al., 2003; Prineas et al., 1993; Prineas and Connell, 1979; 
Raine and Wu, 1993; Lassmann et al., 1997]. Oligodendrocyte precursor cells, after 
maturation into mature oligodendrocytes, generate thin myelin sheaths and could therefore 
contribute to recovery in MS patients. Remyelination in MS is limited. The cause of 
remyelination failure in MS is unknown, but several mechanisms have been proposed, such 
as restricted oligodendrocyte precursor cell migration, maturation and a growth inhibitory 
environment [Franklin, 2002; Wolswijk, 2002; John et al., 2002; Charles et al., 2002]. 
Macrophages could play an important role in remyelination as well [Doring and Yong, 
2011].  
It is clear from the above that macrophages are an important characteristic defining lesion 
stage. They likely play a central role in lesion formation in MS. In the next sections, we will 
describe the role of these immune cells in disease and particularly in MS in more detail. 
3. Macrophages in MS 
3.1 Macrophages and innate immunity 
Macrophages (meaning “big eaters”) are phagocytic cells that play a vital role in innate 
immunity, the first line of defense against pathogens. Cells of the innate immune system 
such as macrophages are able, to some extent, to discriminate between “self” and “non-
self” antigens (reviewed by Janeway [Janeway, Jr. and Medzhitov, 2002]). Via a limited 
number of germline-encoded pattern recognition receptors, macrophages recognize 
highly conserved structures from bacteria, viruses and fungi. Several different families of 
pattern recognition receptors have been identified, for example macrophage scavenger 
receptors and the family of Toll-like receptors [Takeda and Akira, 2005; Akira et al., 2006]. 
After recognition, the binding of the receptor with its ligand on the pathogen, 
macrophages usually engulf the pathogen, a process called phagocytosis. This process 
results in the containment of microbes in the phagosome, which fuses with lysosomal 
vesicles containing a multitude of microbicidal products. Both oxygen-dependent, called 
the respiratory burst, and oxygen-independent microbicidal mechanisms exist. The 
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respiratory burst uses an enzymatic complex called nicotinamide adenine dinucleotide 
phosphate reduced (NADPH) oxidase. Upon stimulation active NADPH oxidase forms. 
This active complex transfers two electrons from NADPH to two molecules of oxygen to 
form superoxide anion [DeLeo et al., 1999; Babior, 1999]. From this superoxide anion other 
ROS, such as hydrogen peroxide, are formed [Babior, 1999]. Oxygen-independent 
microbicidal mechanisms include acidification of the phagolysosome, nutrient depletion 
and antimicrobial proteins or peptides. 
Macrophages differentiate from circulating monocytes. Once a monocyte migrates into a 
specific tissue, during steady-state or inflammation, it develops into a macrophage. 
Macrophages are present in virtually all tissues and usually specialize according to the 
tissue they are in, for instance osteoclasts (in bone), Kupffer cells (in liver) and microglia (in 
the CNS) [Gordon and Taylor, 2005].  
Next to their role in innate immunity they have an important function in tissue homeostasis, 
since they are crucial for the clearance of apoptotic cells and the remodeling and repair of 
tissues after inflammation [Gordon, 1986; Gordon, 1998]. Phagocytosis of apoptotic cells 
does not induce the expression of inflammatory mediators in unstimulated macrophages 
[Kono and Rock, 2008].  
During an infection macrophages also clear cellular debris of necrotic cells that contain 
endogenous danger signals, such as heat-shock proteins and nuclear proteins [Zhang and 
Mosser, 2008]. The detection of these danger signals alters the physiology of the 
macrophages, including expression of cell surface proteins, cytokines and pro-inflammatory 
mediators, increasing immune function of macrophages. However, macrophages can 
respond to many signals in the microenvironment of tissues and not all increase immune 
function.  
3.2 Macrophage activation results in different subtypes 
Macrophages are highly plastic cells and are able to respond to a variety of environmental 
cues changing their phenotype and physiology, resulting in different subtypes of 
macrophages. These different subtypes of macrophages have different functions in immune 
response, homeostasis and tissue repair [Gordon, 2003; Mosser, 2003; Mosser and Edwards, 
2008].  
Based on activation pathways several subtypes of macrophages have been described 
[Edwards et al., 2006b; Martinez et al., 2008]. The two most studied subtypes are: 1) the 
classically activated macrophages (CA, also called M1), induced by interferon-gamma  
(IFN-┛) and lipopolysaccharide (LPS); 2) the alternatively activated macrophages (AA, also 
called M2), stimulated by IL-4/13 and/or glucocorticoids. In 1992 Stein et al. introduced the 
concept of alternatively activated macrophages [Stein et al., 1992]. In contrast to the 
classically activated macrophages, macrophages stimulated with interleukin-4 (IL-4) 
increased the expression of mannose receptor (MR). Another study showed that Th1 
cytokines (e.g. IFN-┛) and Th2 cytokines (e.g. IL-4) induced two distinct functional states in 
macrophages. Exposure of macrophages to Th2 cytokines led to an upregulation of certain 
phagocytic receptors and arginase, which reduced ability to kill intracellular pathogens, 
while Th1 cytokines led to induction of inducible nitric oxide synthase (iNOS) in 
macrophages [Modolell et al., 1995].  
CA macrophages are cytotoxic and secrete high amounts of oxygen and nitrogen radicals in 
order to kill pathogens [Nathan and Shiloh, 2000]. CA macrophages also produce pro-
inflammatory cytokines [O'Shea and Murray, 2008]. In mice, CA macrophages are  
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 M1 macrophage 
Function Th1 response, microbicidal, 
cytotoxic, tumour resistance 
Surface markers MHCII, CD86, CD80, CD40, 
CD1 1b, FCγRI, FCγRII, CCR7 
Cytokines and 
chemokines 
IL-1┚, IL-6, IL-8, IL-12, IL-23, 
TNF-α 
CCL2, CCL5, CXCL9, CXCL10 
Extracellular 
mediators 
Release of superoxide and NO 
  
 M2 macrophage 
Function Th2 response, allergy, parasite 
response, tissue repair, 
immunomodulatory 
Surface markers MR (CD206), CD163, CD23, 
CD36, MSR1, Dectin1, DCIR, 
MARCO, CCR2, E-cadherin 
Cytokines and 
chemokines 
IL-1Ra, IL-10 
CCL13, CCL14, CCL16, CCL17, 
CCL22 
Extracellular 
mediators 
Fibronectin 1, IGF, PDGF-C, 
TGF-┚, FXIIIa, collagen IV 
Fig. 1. Functions and characteristic markers of macrophage activation types. Macrophages 
can change their phenotype and function in response to signals from the environment.  
The most studied phenotypes are M1 and M2 macrophages. M1 macrophages are induced 
in vitro by IFN-┛, LPS and/or TNF-α, while the induction of the M2 phenotype requires  
IL-4/13, IL-10, glucocorticoids or TGF-┚  
characterized by their production of nitric oxide (NO) [Edwards et al., 2006b; MacMicking et 
al., 1997; Hibbs, Jr., 2002]. Human macrophages derived from circulating monocytes do not 
generally produce NO [Mosser, 2003], therefore other markers should be used to 
discriminate between CA and AA macrophages, such as MR, E-cadherin [Van den Bossche 
J. et al., 2009], CD40 [Zeyda et al., 2007] and Fc-gamma receptor I (Fc┛RI). CA macrophages 
are essential for host defence [Gordon and Taylor, 2005; Nathan, 2008] and tumor killing. 
The pro-inflammatory mediators produced by CA macrophages can cause extensive 
damage to the host.  
AA macrophages seem to play a role in immune suppression and tissue repair, due to 
production of anti-inflammatory cytokines and extracellular matrix components and lack 
of production of NO [Edwards et al., 2006b]. The most commonly used distinctive marker 
for AA macrophages, in mice, is the high expression and activity of arginase [Edwards et 
al., 2006b]. Due to the activation of arginase, arginine is converted to ornithine, a 
precursor for polyamines and collagen, which contributes to the production of 
extracellular matrix [Kreider et al., 2007; Albina et al., 1990; Gratchev et al., 2001; Hesse et 
al., 2001]. Furtermore, the polyamines produced can influence production of cytokines and 
suppress clonal expansion of lymphocytes, thereby regulating the immune response 
[Cordeiro-da-Silva et al., 2004].  
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Functional differences can be observed between CA and AA macrophages. As mentioned 
above, due to the production of ROS, CA macrophages are efficient in the killing of bacteria, 
while AA macrophages do not produce ROS and are therefore less efficient in killing 
bacteria [Gordon and Taylor, 2005]. Furthermore, CA macrophages are efficient antigen 
presenting cells, while AA macrophages are not [Edwards et al., 2006b]. CA macrophages 
are also more efficient in activating T-cell proliferation compared to AA macrophages 
[Edwards et al., 2006b]. AA macrophages are involved in scar formation, since they enhance 
fibrogenesis, while CA macrophages do not. AA macrophages stimulate proliferation and 
activation of fibroblasts, by expression and release of potent fibrogenic growth factors, like 
transforming growth factor-beta (TGF-┚) and platelet derived growth factor (PDGF) [Song 
et al., 2000]. The angiogenic potential of AA macrophages is higher compared to CA 
macrophages [Kodelja et al., 1997]. Due to the production of growth factors and stimulation 
of angiogenesis, AA macrophages are considered tumor promoting. In vitro CA 
macrophages were shown to be cytotoxic to tumor cells but not to normal cells [Romieu-
Mourez et al., 2006]. 
3.3 Macrophages in MS lesion formation and repair 
It is widely accepted that macrophages play an important role in MS pathology. 
Macrophages are implicated in mechanisms that lead to demyelination and axonal damage 
[Bitsch et al., 2000; Kuhlmann et al., 2002; Trapp et al., 1998; Koning et al., 2007; Huitinga et 
al., 1990; Heppner et al., 2005; Hendriks et al., 2005; Newman et al., 2001]. Inflammatory 
infiltrates in MS lesions contain large amounts of macrophages. In experimental 
autoimmune encephalomyelitis (EAE), an animal model for MS, it has been shown that 
elimination of infiltrating macrophages reduced both clinical signs and axonal damage 
[Heppner et al., 2005]. Furthermore, during spinal cord injury (SCI), elimination of 
infiltrating macrophages increased axonal repair and functional outcome [Popovich et al., 
1999; Stirling et al., 2004]. Clinical signs of EAE were significantly enhanced when the 
macrophage inhibitory signal of CD200/CD200R between neurons and macrophages was 
blocked [Koning et al., 2007]. This suggests a direct link between increased macrophage 
activity and aggravated disease course in EAE. Finally, macrophages are able to secrete a 
plethora of neurotoxic substances, such as matrix metalloproteinases [Newman et al., 2001], 
reactive oxygen species (ROS) [Nathan and Shiloh, 2000] and nitric oxide (NO) [Smith et al., 
2001]. These studies all indicate that macrophages are detrimental.  
However the role of macrophages is more complex. Several studies have shown that 
activated macrophages can actually be beneficial during CNS repair. During SCI 
macrophages can create a growth-permissive environment in which axonal regeneration can 
take place [Rapalino et al., 1998; Barrette et al., 2008]. In MS lesions, activated macrophages 
can be observed in areas with increased growth-associated protein-43 (GAP-43) expression 
[Teunissen et al., 2006]. In vitro AA macrophage conditioned medium has been found to 
promote axonal outgrowth [Kigerl et al., 2009]. Furthermore, macrophages are beneficial 
because they remove myelin debris, which is growth inhibiting for axons [Baer et al., 2009; 
Kotter et al., 2006], they release growth factors [Song et al., 2000; Kodelja et al., 1997] and 
they support axonal repair [Shechter et al., 2009; Bouhy et al., 2006; Batchelor et al., 2002]. 
These different roles ascribed to macrophages could be due to polarization in macrophage 
activation [Edwards et al., 2006a; Mosser and Edwards, 2008; Mantovani et al., 2004a] 
(Figure 1).  
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4. Models for MS 
4.1 In vivo models 
Research on the mechanisms of demyelinating diseases is highly dependent on experimental 
animal models, due to the inaccessibility of the human brain for experimental research. Most 
frequently allergic autoimmune encephalitis (EAE) models are used as a model for MS. In 
EAE, an autoimmune reaction is induced by injection of myelin proteins or myelin-specific 
inflammatory T-cells into rats or mice. Disability starts with loss of tail tonus, leading to 
complete paralysis, which can be recovered. Demyelination occurs after a chronic induction 
paradigm. The model poses very serious discomfort to the many animals involved. Other 
animal models use viruses or chemical agents such as cuprizone or lysophosphatidylcholine 
(LPC) to induce demyelination [Ercolini and Miller, 2006; Matsushima and Morell, 2001; 
Woodruff and Franklin, 1999]. Another model that is currently increasingly used is the 
mutant shiverer mouse that carries a deletion in the myelin basic protein (MBP) gene [Nave, 
1994]. Several drawbacks of using animal models are: i) per animal only one condition can 
be tested, making the use of many animals unavoidable, ii) investigating the mechanism 
behind demyelination at a cellular level is difficult, due to the complex interactions of the 
CNS with the immune system, iii) in vivo it is very difficult to control all experimental 
conditions.  
4.2 In vitro models 
Only few alternative in-vitro models for de- and remyelination are available. This is due to 
the complex interactions between axons, oligodendrocytes and astrocytes needed for the 
development of multilayered myelin around axons, which cannot be accomplished by cell 
lines or monolayer cultures. A demyelination model in slice cultures has been described 
using LPC [Birgbauer et al., 2004; Miron et al., 2010]. Slice cultures contain intact myelin of 
specific brain areas, and are therefore very suitable for experiments. A drawback, but also 
advantage, of the use of slice cultures is the fact that the cellular composition of the slice can 
not be altered. Furthermore, the top and bottom layer of the slice consists of damaged cells, 
which might influence the behavior of the layers underneath. 
Another good and flexible in vitro model for the CNS is the culture of 3-dimensional brain 
spheroids. Spheroids are formed by continuous rotation of a single cell suspension of 
primary brain cells. These cells aggregate within 24 hours and start to differentiate. The 
result after 4 weeks of maturation is a spheroid containing all different brain cell types that 
make 3-dimensional contacts [Figure 2: 3-dimensional aspect of spheroid cultures]. The high 
level of differentiation is exemplified by the presence of myelinated axons and spontaneous 
synaptic activity. The model has been used for studying brain development, neurotoxicity, 
and neurodegenerative diseases [Berglund et al., 2004; Diemel et al., 2004; Honegger and 
Richelson, 1976].  
In previous studies, immune-mediated demyelination has been induced in this model, using 
anti-myelin antibodies and complement [Diemel et al., 2004; Loughlin et al., 1994]. The 
major drawback of that model is that only modest and variable effects of antibodies were 
observed (personal observations C. Teunissen). We were able to induce non-inflammatory 
demyelination using LPC as well as subsequent recovery after LPC-withdrawal, in rodent 
brain spheroids. The effect of LPC was specific for myelin, since other CNS cell types 
present in the cultures were only slightly or not affected [Vereyken et al., 2009]. After 
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cessation of LPC treatment, remyelination was observed in these culture (Figure 3) . These 
data demonstrate the potential of this model to study several fundamental aspects of de- 
and remyelination. 
 
 
Copyright permission has been obtained from Brain Research. 
                                   (A)                                                                              (B) 
Fig. 2. Scanning electron microscopy photograph of a cultured spheroid. (A) Example of  
3-week-old whole brain spheroids showing a typical three-dimensional appearance. Bar 
represents 50 mm. (B) Higher magnification than (A), bar represents 5 mm. Teunissen et al 
2000 [Teunissen et al., 2000] 
5. Macrophage-CNS interaction in an in vitro model for MS 
Microglia are present in spheroids, and these can be activated to study the effects of 
macrophages on myelin formation and demyelination. Alternatively, activated macrophages 
can be supplemented to the cultures. We set out to study whether the spheroid culture 
model is suitable for studying effects of supplemented macrophages. An important first 
question was whether macrophages are able to migrate into the spheroids, which would be 
a benefit of this model over in vivo models as there is no blood brain barrier (BBB) and the 
influence of BBB interruption can be circumvented. Next, we were especially interested to 
determine the effects of macrophages on CNS cell types inside the spheroids. Our 
hypothesis was that CA macrophages would have toxic effects and AA macrophages 
positive effects on myelin, glia and axonal integrity. No studies so far have addressed the 
question if these differential macrophage phenotypes have differential effects on intact CNS 
tissue. Therefore, we also set out to compare the effects of CA and AA macrophages on 
cellular structures within whole brain spheroid cultures.  
5.1 Number of macrophages in spheroids 
First, we established whether macrophages could migrate into the spheroids, and whether 
the numbers were similar for the CA and AA macrophage phenotypes. For this, we cultured 
rat whole brain spheroids during 4 weeks, to reach optimal myelin development, and 
exposed them to differently activated macrophages, that were fluorescently labeled, 
[method of macrophage activation: Vereyken et al., 2011] during maximal 1 week. At several 
time points, cryostat sections were cut of the spheroids and the number of spheroids 
containing macrophages were counted.  
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Copyright permission obtained from Brain Research and also from Glia  
Fig. 3. EM picture of demyelinated rat whole brain spheroid cultures. A: After 4 weeks of 
culturing the experiment was started at day 0. After 7 days (5 weeks of culturing) multilayered 
compact myelin was present. See insert for more detail. B: After a week of exposure to LPC 
(three times addition of 0.12 mM LPC), at day 7 (= week 5 of culturing), the myelin layers 
were loosely packed. See insert for more detail. C: Control cultures at day 14 (6 week old 
cultures), show compact myelin. D: At day 14, after 1 week of exposure to LPC and 1 week 
of recovery, LPC-exposed cultures show compact myelin. Bar is 500 nm. E: Quantification of 
the number of myelin sheets present in EM pictures from two separate experiments (four 
pictures from three spheroids). After LPC treatment at 7 days 12.5 myelin sheets per picture 
were counted. When compared with control spheroids, 29 myelin sheets per picture, a 
significant decrease of 56% was, therefore, visible. At 14 days, the number of myelin sheets 
was not significantly different between control, 28 myelin sheets per picture, and LPC 
treated, 20 myelin sheets per picture, cultures. Results are presented as mean ± SEM. Open 
bars: control; closed bars: LPC treated; asterisks indicate  
P < 0.05. [Vereyken et al.. 2009] 
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We observed a temporal pattern. After 1 day no macrophages were visible in the spheroids 
(data not shown). At 2 days after macrophage addition, low numbers of macrophages were 
present in spheroids exposed to AA and unstimulated (US) macrophages (data not shown). 
At 3 days macrophages were observed in 40-70% of the spheroid sections (Figure 4A and D). 
After 8 days the macrophage numbers were decreased compared to day 3 (data not shown).  
Most macrophages were associated with spheroids on the outside rim of the spheroid, but 
several also migrated into the center of the spheroids (Figure 4A, B, C). A larger number of 
spheroids contained one or more macrophages when exposed to either AA or US 
macrophages compared to CA macrophages (Figure 4D). These results were in agreement 
with our previous observations showing that AA macrophages have a higher intrinsic 
motility compared to CA macrophages [Vereyken et al., 2011]. Furthermore, CA 
macrophages had been observed to express higher levels of adhesion receptors compared to 
both AA and US macrophages [Vereyken et al., 2011]. Thus, the lower motility and higher 
adhesion could contribute to the lower migration of CA macrophages into spheroids. 
After induction of demyelination, a similar pattern was observed for the differentially 
activated macrophages, i.e. a higher percentage of spheroids contained AA and US 
macrophages (Figure 4E). Taken together, all different macrophage phenotypes could 
migrate into the spheroids, while the extend of migration differed between phenotypes.  
5.2 Effect of differentially activated macrophages on CNS cells in spheroid cultures 
Next, we tested whether CA and AA macrophages had and effect on CNS cells in the 
spheroids and whether the effects were dependent on the macrophage phenotype. We 
quantified the total immunoreactivity per spheroid section using image analysis software 
[Vereyken et al., 2009]. Figure 5A-D. show the results of the quantification of the 
immunereactivity (IR). MBP immunereactivity was 50% increased in spheroid cultures 
exposed to CA and AA macrophages, compared to control spheroid cultures (spheroids 
exposed to unstimulated macrophages and spheroid cultures without macrophages). Figure 
6A-D shows representative images of MBP staining after exposure of intact spheroids to 
differently activated macrophages. In control spheroids, MBP IR was present in structures in 
the center and at the borders (Figure 6A). In the spheroids exposed to unstimulated 
macrophages a similar picture was observed, although, in some spheroids a higher number 
of MBP-positive structures near the border was observed (Figure 6B). Note that in this 
specific section, no intact macrophages are visible, which is likely due to the relatively low 
numbers of macrophages inside the spheroids in combination with the low thickness of the 
sections. After exposure to CA macrophages, a higher mean IR was observed at the spheroid 
border (Figure 6C). The mean IR was also increased in spheroids exposed to AA 
macrophages (Figure 6D). This increase was mainly observed in the area just below the 
border. 
GFAP IR was not affected by addition of the macrophages. GFAP IR was slightly lower in 
spheroids exposed to AA macrophages compared to spheroids exposed to CA macrophages 
(Fig 5B). ┚-tubulin IR was decreased by 50% in CA macrophage-exposed spheroids 
compared to control spheroids, not exposed to any macrophages. Tubulin staining was 
present in center of the control spheroids, as described before [Vereyken et al., 2009]. After 
exposure of the spheroids to CA macrophages especially the ┚-tubulin IR in the center of the 
spheroids was decreased (Figure 5C). A slight increase in GAP-43 IR was observed in 
spheroids exposed to CA macrophages compared to control spheroids not exposed to 
macrophages (Figure 5D).  
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Fig. 4. Migration of macrophages in whole brain spheroid cultures. Mature spheroids were 
exposed to unstimulated (A); classically activated (CA); of alternatively activated (AA) 
macrophages during three days. Macrophages were labelled with DiI before addition to the 
cultures. Sections were prepared and nuclei stained with Hoechst. Bar in A is 200 µm. Figure 
4D and E: Quantification of migration of differently activated macrophages in whole brain 
spheroids. D: The number of positive spheroids was determined as the number of spheroids 
containing one or more macrophages/total number of control spheroids. A trend could be 
seen of a lower migration of CA macrophages into spheroids compared to unstimulated and 
AA macrophages. E: Quantification of migration of macrophages is higher in demyelinated 
spheroids. Unstimulated macrophages were present in 73% (± 6) of the LPC-demyelineated 
spheroids. Spheroids exposed to CA macrophages. Only 45% (± 6) of the LPC-demyelineated 
spheroids were positive for CA macrophages. With AA macrophages the percentage of 
spheroids positive was 80 % (± 24) 
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Fig. 5. Quantification of effects of differentially activated macrophages on immunereactivity 
of specific CNS cell proteins in spheroid cultures. Unstim=unstimulated macrophages;  
CA: classically activated macrophages; AA: Alternatively activated macrophages. Four-
weeks old whole brain spheroid cultures exposed to unstim, CA or AA macrophages during 
3 days. a: P< 0.05 compared to control; b: P<0.05 compared to unstimulated macrophages;  
c: P<0.05 for differences between CA and AA macrophages 
5.3 Discussion of the experimental results in spheroid cultures 
The first aim of the experiments described above was to study whether macrophages can 
migrate into the spheroid cultures. This was indeed the case. Externally supplemented 
macrophages can be labeled to trace them within the spheroid and we observed that they 
can migrate into the center of the spheroid.  
The second aim was to study effects of classically and alternatively activated macrophages 
on cellular structures of whole brain spheroid cultures. Our hypothesis was that CA 
macrophages would have toxic effects and that AA macrophages have positive effects on 
myelin and axonal integrity. Our results were in part supportive for this hypothesis: CA 
macrophages had a slight negative effect on tubulin immune reactivity in intact spheroids, 
while AA macrophages had no effect on tubulin immune reactivity. This indicates that CA 
macrophages were toxic to neurons, while AA macrophages were not. These data are in 
agreement with our observations in monolayers (EJFV Unpublished observation). The 
GFAP immunereactivity was slightly higher in CA exposed macrophages compared to AA 
exposed macrophages. However, for many of our read-outs there were no substantial 
differences between the differently activated macrophages. A similar positive effect of both  
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Fig. 6. Effects of differentially activated macrophages on immunereactivity of myelin basic 
protein (MBP) in spheroid cultures. Four-weeks old whole brain spheroid cultures were 
exposed to unstim, CA or AA macrophages during 3 days. A: MBP immune reactivity in 
control spheroids without exposure to macrophages.; B-D: MBP immune reactivity in 
spheroids exposed to (B) unstimulated macrophages, (C) classically activated (CA) 
macrophages, and (D) Alternatively activated macrophages (AA). E: GFAP IR in spheroids 
exposed to CA macrophages; F: GFAP IR in spheroids exposed to AA macrophages.  
G: ┚-tubulin IR in control spheroids. H: ┚-tubulin IR in spheroids exposed to CA 
macrophages. Bar in A and G= 200 µm 
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CA and AA macrophages on MBP immunereactivity in spheroids was observed. The lack of 
large differences between the different macrophage phenotypes could be related to the 
length of the experiments and the flexibility of the macrophage phenotypes, as a 
fundamental characteristic of macrophages is their ability to change their phenotype and 
they could all have a similar phenotype after a few days of contact with the CNS tissue. 
However, the duration of the experiments was three days, and we observed differences in 
migration between the phenotypes after 3 days. The different phenotypes do contain similar 
receptors, and it is possible that MBP expression is influenced by growth factors that may be 
differently, but at least sufficient on both phenotypes for induction of the observed.  
Taken together, our results have shown that CA and AA macrophages can both affect 
myelin formation in spheroid cultures. Future studies must show whether macrophages can 
enhance myelin formation after demyelination and the conditions under which they can 
have regenerative effects. 
6. Future perspectives 
There are various in vivo and in vitro models for de- and remyelination in MS. The use of 
each of the models will depend on the research question. In vitro models provide the 
possibility to study direct effects on CNS cell types, without interference of other processes. 
Furthermore, access to CNS cell types is not hampered by the blood brain barrier. 
Furthermore, use of in in vitro models leads to a reduction of animal suffering. Nevertheless, 
we do not expect in vitro results to be directly translatable to the human situation and thus 
an intermediate step in vivo will be needed, but this can be on a limited scale when the range 
of conditions are narrowed by in vitro experiments.  
In MS lesions, macrophages with the CA phenotype could inhibit repair or propagate lesion 
formation, since CA macrophages have been shown to be neurotoxic while AA activation 
abolished the neurotoxic effects. In MS lesions it could therefore be beneficial to reduce the 
CA phenotype and promote the AA phenotype. Possible mechanisms to skew the 
macrophage phenotype in the CNS are interesting to investigate, in order to design anti-
inflammatory therapies. Here, we discuss these options.  
6.1 Skewing of macrophage phenotype 
Glucocorticoids are an accepted therapy during MS. Treatment with glucocorticoids might 
be a means of skewing the activational phenotype, since exposure to glucocorticoids induce 
a wound healing phenotype in macrophages in vitro [Mosser and Edwards, 2008; Gordon, 
2003]. A glucocorticoid receptor ligand was found to attenuate experimental autoimmune 
neuritis, decrease the expression of inflammatory cytokines and iNOS and induce a M2 
phenotype in vitro [Zhang et al., 2009].  
Evidence for the possibility that substances in the periphery can influence CNS cells has 
been observed previously. In the CNS microglia have been shown to switch cytokine profile, 
from relatively anti-inflammatory to pro-inflammatory CA phenotype, after induction  
of Wallerian degeneration followed by systemic injection of LPS [Palin et al., 2008].  
The peripheral LPS injection also led to a decrease in neurofilament staining, indicating  
that neurodegeneration is increased. Similar results were found with a mouse model for 
prion disease, more inflammation and neuronal apoptosis after systemic LPS injection 
[Cunningham et al., 2005]. Likewise, glucocorticoids and glatiramer acetate, when applied 
peripherally, could influence the phenotype of microglia and macrophages inside the CNS.  
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It would therefore be interesting to determine the effect of glucocorticoid treatment on the 
macrophage phenotype in the CNS. Furthermore, since in MS lesions the macrophages 
predominantly express markers of the CA phenotype, it would be useful to study whether 
AA macrophages that enter a pro-inflammatory environment would be able to keep their 
phenotype. Could AA macrophages be able to exert positive effects in a pro-inflammatory 
environment? These questions can be investigated using in vitro models, such as the 
spheroid model, representing the CNS environment. 
6.2 Injection of skewed macrophages 
Some investigation into direct treatment with AA macrophages has been performed and 
therapeutic effects have been observed. In a model for murine diabetes a reduction in renal 
and pancreatic injury was seen after treatment with in vitro generated AA macrophages 
[Zheng et al., 2011]. The injection of AA macrophages reduced disease in a model for colitis 
[Hunter et al., 2010]. Furthermore, axonal dieback induced by macrophages was reduced 
after the addition of multipotent adult progenitor cells, which induced the AA phenotype in 
macrophages in vitro [Busch et al., 2011]. During EAE, treatment with substances skewing 
the macrophage phenotype toward an AA phenotype, such as anti-CCL22 [Dogan et al., 
2011] and 2-arachidonoylglycerol [Lourbopoulos et al., 2011], was found to ameliorate the 
disease course and increase the presence of macrophages with an AA phenotype in the 
lesions. In a model for relapsing EAE, the injection of AA macrophages, generated in vitro, 
reduced the development of relapses [Mikita et al., 2011]. Clinical EAE was reversed by the 
adoptive transfer of AA macrophages, which were induced in vitro with glatiramer acetate 
[Weber et al., 2007]. Our studies have shown that macrophage migration towards CNS cell 
types differs upon skewing [Vereyken et al., 2011] and that migration of macrophages in 
spheroids is limited and varies with skewing of the macrophages (Figure 4E). Microinjection 
of skewed macrophages into spheroids or co-culture of differently activated macrophages 
would allow more in depth analysis into the cellular mechanisms behind the effects 
reported in these studies. 
7. Conclusion 
Spheroid cultures are a suitable model to test the effects of novel therapeutics on 
remyelination, e.g. magnitude and speed. Furthermore, this model is very useful to study 
the mechanism of remyelination and the effects of demyelination, for example on axons. 
Using spheroid cultures, cells not endogenous to the CNS, like macrophages, can be 
introduced into the spheroids with relative ease [Loughlin et al., 1994; Loughlin et al., 1997; 
Pardo and Honegger, 2000] as we demonstrated. Both CA and AA macrophages can have 
beneficial effects in an MS lesion. The CA macrophages are very efficient in clearing debris, 
however, they are toxic to neurons. The AA macrophages secrete higher amounts of 
neurotrophins and are not neurotoxic, however they are less efficient in clearing debris. It 
would be of great value if an activational status in macrophages could be reached with an 
increased phagocytic capacity, without the production of neurotoxic substances such as 
ROS, NO and TNF-α, and with the secretion of growth factors. Future research should 
therefore focus on the functional activation status of macrophages stimulated with for 
example glucocorticoids, to enhance the secretion of growth factors and phagocytosis and 
limit secretion of neurotoxic substances. 
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